Page 219 - EJMO-9-1

Eurasian Journal of Medicine and
Oncology Anticoagulant therapy on parathyroid

Therefore, a study was conducted using a combination of In addition, standardized protocols for monitoring
these two medications. microcirculatory changes, parathyroid vasculature, and
In this study, the combination of routine post- biochemical markers would further enhance the accuracy
operative calcium supplementation, anticoagulation and reliability of outcome measures.
therapy, MaiLuoShuTong pills, and daheparin In addition, exploring individualized therapeutic
resulted in a significantly higher incidence of post- regimens, particularly in patients who exhibit complex
operative parathyroid recovery and return to normal comorbid profiles, may reveal more precise indications
function than that in the control group. In patients for combined anticoagulant and traditional Chinese
without permanent hypoparathyroidism, the use of medicine therapy. Such integrative management could
MaiLuoShuTong pills combined with heparin improved advance our understanding of personalized approaches to
parathyroid microcirculation and inhibited thrombosis thyroid surgery and may pave the way for novel preventive
in the parathyroid-feeding microvasculature. This was strategies against permanent hypoparathyroidism.
associated with a reduction in the inflammatory response Ultimately, a collaborative, multidisciplinary approach
in the surgical area. Compared to the control group, involving surgeons, endocrinologists, and integrative
the mean post-operative drainage flow and the time to medicine specialists holds promise for optimizing surgical
Hemovac removal were not significantly different in the outcomes, minimizing post-operative complications,
anticoagulant group. No post-operative bleeding occurred and improving the overall standard of care in thyroid
in either group, and there was no increase in the risk of surgery.
post-operative bleeding, demonstrating the safety and
effectiveness of the treatment. Acknowledgments

5. Conclusion and future prospects None.
This study underscores the potential therapeutic advantage Funding
of combining MaiLuoShuTong pills with dalteparin for
preserving and restoring parathyroid function after total This work was supported by the Zibo Medical and Health
thyroidectomy. By improving microcirculation, reducing Research Project (Grant number: 20230401040).
local inflammation, and preventing parathyroid gland
infarction, this regimen facilitates faster normalization Conflict of interest
of PTH levels, thereby addressing one of the most The authors declare that they have no competing interests.
common and challenging complications of thyroid
surgery, hypoparathyroidism. Such improvements could Author contributions
significantly reduce post-operative morbidity, enhance Conceptualization: Jia Qi Liu, Yu Ding
patients’ quality of life, and ease the long-term economic Data curation: All authors
burdens associated with chronic calcium and Vitamin D Formal analysis: Jia Qi Liu, Yu Ding
supplementation.
Investigation: All authors
Nevertheless, several important considerations Writing – original draft: All authors
warrant further investigation. First, the presence of Writing – review & editing: Jia Qi Liu
comorbid conditions, such as diabetes, hypertension,
hyperlipidemia, and coronary heart disease, among the Ethics approval and consent to participate
study population may have introduced confounding This study was approved by the Ethics Committee of
factors. For instance, diabetes can impair microcirculation Zibo Central Hospital (approval number: 201801020).
and delay glandular recovery, while patients with All procedures in studies involving human participants
coronary heart disease may already be on anticoagulant
or antiplatelet therapy, complicating the assessment of were performed in accordance with the 1964 Helsinki
dalteparin’s efficacy and safety. Future studies should Declaration and its subsequent versions. Informed consent
adopt stricter inclusion and exclusion criteria or perform was obtained from the patients for the anonymous use of
subgroup analyses to elucidate the independent effects of their data for research purposes.
these comorbidities. Second, although the initial results Consent for publication
suggest a favorable risk-benefit profile, larger multicenter,
randomized controlled trials are necessary to confirm Informed consent was obtained from the patient’s form for
these findings, establish optimal dosages and treatment anonymous utilization of their data for research purposes
durations, and assess long-term safety outcomes. and subsequent publication.

Volume 9 Issue 1 (2025) 211 doi: 10.36922/ejmo.8105